




Searching News Database: B-cell
HSMN NewsFeed - 31 Mar 2025
Lomond Therapeutics Completes Second and Third Closings and adds Two New Investors
Lomond Therapeutics Completes Second and Third Closings and adds Two New Investors
HSMN NewsFeed - 13 Jan 2025
Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma
Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma
HSMN NewsFeed - 6 Sep 2023
OncoResponse Announces Appointment of Carol Gallagher to Board of Directors
OncoResponse Announces Appointment of Carol Gallagher to Board of Directors
HSMN NewsFeed - 18 Aug 2023
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
HSMN NewsFeed - 30 Mar 2023
HistoSonics Announces First Ever Kidney Tumor Treatment Using Histotripsy
HistoSonics Announces First Ever Kidney Tumor Treatment Using Histotripsy
HSMN NewsFeed - 28 Sep 2021
ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership
ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership
HSMN NewsFeed - 3 May 2021
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
HSMN NewsFeed - 29 Mar 2021
Phoenix Molecular Designs Appoints Biotech Powerhouse, Michael Varney, Ph.D., to its Advisory Board
Phoenix Molecular Designs Appoints Biotech Powerhouse, Michael Varney, Ph.D., to its Advisory Board
HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 10 Nov 2020
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
HSMN NewsFeed - 24 Mar 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
HSMN NewsFeed - 2 Jan 2020
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
HSMN NewsFeed - 19 Jul 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
HSMN NewsFeed - 8 Jul 2019
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
HSMN NewsFeed - 19 Jun 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
HSMN NewsFeed - 10 Jun 2019
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
HSMN NewsFeed - 8 Apr 2019
HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing
HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing
HSMN NewsFeed - 14 May 2018
GT Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company
GT Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company
HSMN NewsFeed - 26 Apr 2018
Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's Board of Directors
Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's Board of Directors
HSMN NewsFeed - 24 Apr 2018
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors
HSMN NewsFeed - 15 Feb 2018
GT Biopharma Announces Appointment of Shawn M Cross as Chairman and Chief Executive Officer
GT Biopharma Announces Appointment of Shawn M Cross as Chairman and Chief Executive Officer
HSMN NewsFeed - 3 Jan 2018
Denovo Biopharma Opens New R&D Center, Names Chief Medical Officer and Chief Financial Officer
Denovo Biopharma Opens New R&D Center, Names Chief Medical Officer and Chief Financial Officer
HSMN NewsFeed - 3 Apr 2017
BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
HSMN NewsFeed - 27 Jan 2017
Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
HSMN NewsFeed - 12 Sep 2016
Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development
Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development
HSMN NewsFeed - 18 Mar 2016
ProNAi Therapeutics Appoints Jeffrey H. Cooper and Tran Nguyen to its Board of Directors
ProNAi Therapeutics Appoints Jeffrey H. Cooper and Tran Nguyen to its Board of Directors
HSMN NewsFeed - 3 Dec 2015
ProNAi Therapeutics Appoints Dr. Keith Anderson and Dr. Gregg Smith to its Senior Management Team
ProNAi Therapeutics Appoints Dr. Keith Anderson and Dr. Gregg Smith to its Senior Management Team
HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
HSMN NewsFeed - 16 Jan 2014
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
HSMN NewsFeed - 6 Jan 2014
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
HSMN NewsFeed - 4 Dec 2013
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
HSMN NewsFeed - 15 Oct 2013
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
HSMN NewsFeed - 8 Oct 2013
Molecular Templates Announces $8.5M Series C Financing and $10.6M Grant Funding
Molecular Templates Announces $8.5M Series C Financing and $10.6M Grant Funding
HSMN NewsFeed - 19 Aug 2013
Market Access Granted in France for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Market Access Granted in France for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
HSMN NewsFeed - 8 Jul 2013
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
HSMN NewsFeed - 21 Dec 2012
Spectrum Pharmaceuticals Announces Achievement of Primary Endpoint in Belinostat Registrational Trial
Spectrum Pharmaceuticals Announces Achievement of Primary Endpoint in Belinostat Registrational Trial
HSMN NewsFeed - 30 Jul 2012
Biovest Advances Process Seeking European Marketing Approval for BiovaxID(TM) Personalized Lymphoma Vaccine
Biovest Advances Process Seeking European Marketing Approval for BiovaxID(TM) Personalized Lymphoma Vaccine
HSMN NewsFeed - 31 May 2012
Cell Therapeutics' Pixuvri(R) Phase 3 Clinical Trial Results Published in The Lancet Oncology
Cell Therapeutics' Pixuvri(R) Phase 3 Clinical Trial Results Published in The Lancet Oncology
HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
HSMN NewsFeed - 14 Jul 2011
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
HSMN NewsFeed - 22 Mar 2011
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
HSMN NewsFeed - 30 Aug 2010
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
HSMN NewsFeed - 29 Jul 2010
Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & Development
Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & Development
HSMN NewsFeed - 19 Mar 2010
Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers
Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers
HSMN NewsFeed - 7 Dec 2009
Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board
Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board
HSMN NewsFeed - 3 Nov 2009
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
HSMN NewsFeed - 26 Aug 2009
Genmab Announces Positive Top-Line Results for Arzerra(TM) in Front Line NHL
Genmab Announces Positive Top-Line Results for Arzerra(TM) in Front Line NHL
HSMN NewsFeed - 31 Jul 2009
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
HSMN NewsFeed - 19 Jun 2009
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
HSMN NewsFeed - 11 May 2009
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
HSMN NewsFeed - 22 Apr 2009
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
HSMN NewsFeed - 29 Jan 2009
Immunomedics Reports Properties and Structure-Function Relationships of Veltuzumab
Immunomedics Reports Properties and Structure-Function Relationships of Veltuzumab
HSMN NewsFeed - 6 Oct 2008
Biolex Therapeutics Enters Into Agreement to Acquire Full Locteron(R) Commercial Rights
Biolex Therapeutics Enters Into Agreement to Acquire Full Locteron(R) Commercial Rights
HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
HSMN NewsFeed - 18 Aug 2008
Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
HSMN NewsFeed - 18 Mar 2008
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
HSMN NewsFeed - 25 Feb 2008
GPC Biotech Announces Corporate Restructuring and Provides Pipeline Update
GPC Biotech Announces Corporate Restructuring and Provides Pipeline Update
HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
HSMN NewsFeed - 19 Feb 2008
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
HSMN NewsFeed - 6 Dec 2007
Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting
Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting
HSMN NewsFeed - 20 Nov 2007
Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
HSMN NewsFeed - 16 Oct 2007
Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
HSMN NewsFeed - 4 Jun 2007
Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
HSMN NewsFeed - 2 Jun 2007
Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
HSMN NewsFeed - 30 May 2007
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
HSMN NewsFeed - 26 Mar 2007
Enzastaurin Granted Orphan Drug Status for Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
Enzastaurin Granted Orphan Drug Status for Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
HSMN NewsFeed - 21 Feb 2007
Protalex Appoints Edward W. Bernton, MD as Medical Director and Updates Development Plans for 2007
Protalex Appoints Edward W. Bernton, MD as Medical Director and Updates Development Plans for 2007
HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
HSMN NewsFeed - 31 Oct 2006
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
HSMN NewsFeed - 12 Oct 2006
Favrille Appoints Former Eli Lilly Executive Michael Eagle Chairman of the Board
Favrille Appoints Former Eli Lilly Executive Michael Eagle Chairman of the Board
HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
HSMN NewsFeed - 11 May 2006
FDA Grants Accentia Biopharmaceuticals, Inc.'s Majority-Owned Subsidiary Fast Track Status for BiovaxID(TM)
FDA Grants Accentia Biopharmaceuticals, Inc.'s Majority-Owned Subsidiary Fast Track Status for BiovaxID(TM)
HSMN NewsFeed - 10 May 2006
UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab
UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab
HSMN NewsFeed - 10 May 2006
Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
Additional items found! 208

Members Archive contains
208 additional stories matching:
B-cell
(Password required)
B-cell
(Password required)